Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1993 Jan;91(1):38–45. doi: 10.1172/JCI116196

Protection by antibiotics against myeloperoxidase-dependent cytotoxicity to lung epithelial cells in vitro.

A Cantin 1, D E Woods 1
PMCID: PMC329992  PMID: 8380814

Abstract

Myeloperoxidase, in the presence of noncytotoxic concentrations of H2O2, was used to induce cytotoxicity to the lung epithelial cell line, AKD. When the cationic aminoglycosides, tobramycin and gentamicin were added to the cells in the presence of myeloperoxidase and H2O2, cytotoxicity was completely inhibited. In addition, tobramycin prevented cytotoxicity induced by cystic fibrosis sputum and H2O2. Protection against myeloperoxidase and H2O2 was also observed with the thioether-containing antibiotics, ticarcillin and ceftazidime, but at higher concentrations than with the aminoglycosides. Analysis of spectral properties, dimethylsulfoxide-mediated reduction, and ethyl acetate/NaCl partitioning, demonstrated that aminoglycosides converted HOCl to hydrophilic noncytotoxic chloramines, but were unable to prevent the oxidation of sulfhydryls and methionine by HOCl. In contrast, ticarcillin and ceftazidime were highly effective inhibitors of HOCl-mediated sulfhydryl and methionine oxidation. These results suggest that aminoglycosides protect lung epithelial cells against myeloperoxidase-dependent oxidant injury by binding to anionic cell surfaces and converting HOCl to hydrophilic noncytotoxic chloramines, whereas penicillins and cephalosporins are potent HOCl scavengers capable of protecting critical extracellular molecules against oxidation.

Full text

PDF
38

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alderson P. O., Secker-Walker R. H., Stominger D. B., Markham J., Hill R. L. Pulmonary deposition of aerosols in children with cystic fibrosis. J Pediatr. 1974 Apr;84(4):479–484. doi: 10.1016/s0022-3476(74)80664-5. [DOI] [PubMed] [Google Scholar]
  2. Cantin A. M., Fells G. A., Hubbard R. C., Crystal R. G. Antioxidant macromolecules in the epithelial lining fluid of the normal human lower respiratory tract. J Clin Invest. 1990 Sep;86(3):962–971. doi: 10.1172/JCI114798. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cantin A. M., North S. L., Fells G. A., Hubbard R. C., Crystal R. G. Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J Clin Invest. 1987 Jun;79(6):1665–1673. doi: 10.1172/JCI113005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cantin A., Bilodeau G., Bégin R. Granulocyte elastase-mediated proteolysis of alpha 1-antitrypsin in cystic fibrosis bronchopulmonary secretions. Pediatr Pulmonol. 1989;7(1):12–17. doi: 10.1002/ppul.1950070105. [DOI] [PubMed] [Google Scholar]
  5. Cochrane C. G., Spragg R., Revak S. D. Pathogenesis of the adult respiratory distress syndrome. Evidence of oxidant activity in bronchoalveolar lavage fluid. J Clin Invest. 1983 Mar;71(3):754–761. doi: 10.1172/JCI110823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dougherty H. W., Hen A., Kuehl F. A., Jr The role of polymorphonuclear peroxidase-dependent oxidants in inflammation. Agents Actions Suppl. 1980;7:167–173. [PubMed] [Google Scholar]
  7. Goldstein W., Döring G. Lysosomal enzymes from polymorphonuclear leukocytes and proteinase inhibitors in patients with cystic fibrosis. Am Rev Respir Dis. 1986 Jul;134(1):49–56. doi: 10.1164/arrd.1986.134.1.49. [DOI] [PubMed] [Google Scholar]
  8. Hodson M. E., Penketh A. R., Batten J. C. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet. 1981 Nov 21;2(8256):1137–1139. doi: 10.1016/s0140-6736(81)90588-2. [DOI] [PubMed] [Google Scholar]
  9. Hoiby N. Epidemiological investigations of the respiratory tract bacteriology in patients with cystic fibrosis. Acta Pathol Microbiol Scand B Microbiol Immunol. 1974 Aug;82(4):541–550. [PubMed] [Google Scholar]
  10. Humes H. D., Weinberg J. M., Knauss T. C. Clinical and pathophysiologic aspects of aminoglycoside nephrotoxicity. Am J Kidney Dis. 1982 Jul;2(1):5–29. doi: 10.1016/s0272-6386(82)80039-5. [DOI] [PubMed] [Google Scholar]
  11. Johnson D., Travis J. The oxidative inactivation of human alpha-1-proteinase inhibitor. Further evidence for methionine at the reactive center. J Biol Chem. 1979 May 25;254(10):4022–4026. [PubMed] [Google Scholar]
  12. Johnson R. J., Couser W. G., Chi E. Y., Adler S., Klebanoff S. J. New mechanism for glomerular injury. Myeloperoxidase-hydrogen peroxide-halide system. J Clin Invest. 1987 May;79(5):1379–1387. doi: 10.1172/JCI112965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kalyanaraman B., Sohnle P. G. Generation of free radical intermediates from foreign compounds by neutrophil-derived oxidants. J Clin Invest. 1985 May;75(5):1618–1622. doi: 10.1172/JCI111868. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kanofsky J. R., Wright J., Miles-Richardson G. E., Tauber A. I. Biochemical requirements for singlet oxygen production by purified human myeloperoxidase. J Clin Invest. 1984 Oct;74(4):1489–1495. doi: 10.1172/JCI111562. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kelly H. W., Lovato C. Antibiotic use in cystic fibrosis. Drug Intell Clin Pharm. 1984 Oct;18(10):772–783. doi: 10.1177/106002808401801001. [DOI] [PubMed] [Google Scholar]
  16. Kniazeff A. J., Stoner G. D., Terry L., Wagner R. M., Hoppenstand R. D. Characteristics of epithelial cella cultured from feline lung. Lab Invest. 1976 May;34(5):495–500. [PubMed] [Google Scholar]
  17. Learn D. B., Brestel E. P., Seetharama S. Hypochlorite scavenging by Pseudomonas aeruginosa alginate. Infect Immun. 1987 Aug;55(8):1813–1818. doi: 10.1128/iai.55.8.1813-1818.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lehrer R. I. Inhibition by sulfonamides of the candidacidal activity of human neutrophils. J Clin Invest. 1971 Dec;50(12):2498–2505. doi: 10.1172/JCI106750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. MacLusky I. B., Gold R., Corey M., Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol. 1989;7(1):42–48. doi: 10.1002/ppul.1950070110. [DOI] [PubMed] [Google Scholar]
  20. Maier K., Leuschel L., Costabel U. Increased levels of oxidized methionine residues in bronchoalveolar lavage fluid proteins from patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1991 Feb;143(2):271–274. doi: 10.1164/ajrccm/143.2.271. [DOI] [PubMed] [Google Scholar]
  21. Matheson N. R., Wong P. S., Travis J. Isolation and properties of human neutrophil myeloperoxidase. Biochemistry. 1981 Jan 20;20(2):325–330. doi: 10.1021/bi00505a015. [DOI] [PubMed] [Google Scholar]
  22. Mohammed J. R., Mohammed B. S., Pawluk L. J., Bucci D. M., Baker N. R., Davis W. B. Purification and cytotoxic potential of myeloperoxidase in cystic fibrosis sputum. J Lab Clin Med. 1988 Dec;112(6):711–720. [PubMed] [Google Scholar]
  23. Parry M. F., Root R. K., Metcalf J. A., Delaney K. K., Kaplow L. S., Richar W. J. Myeloperoxidase deficiency: prevalence and clinical significance. Ann Intern Med. 1981 Sep;95(3):293–301. doi: 10.7326/0003-4819-95-3-293. [DOI] [PubMed] [Google Scholar]
  24. Pechere J. C., Dugal R. Clinical pharmacokinetics of aminoglycoside antibiotics. Clin Pharmacokinet. 1979 May-Jun;4(3):170–199. doi: 10.2165/00003088-197904030-00002. [DOI] [PubMed] [Google Scholar]
  25. Pekoe G., Van Dyke K., Peden D., Mengoli H., English D. Antioxidation theory of non-steroidal anti-inflammatory drugs based upon the inhibition of luminol-enhanced chemiluminescence from the myeloperoxidase reaction. Agents Actions. 1982 Jul;12(3):371–376. doi: 10.1007/BF01965406. [DOI] [PubMed] [Google Scholar]
  26. SCHULTZ J., SHMUKLER H. W. MYELOPEROXIDASE OF THE LEUCOCYTE OF NORMAL HUMAN BLOOD. II. ISOLATION, SPECTROPHOTOMETRY, AND AMINO ACID ANALYSIS. Biochemistry. 1964 Sep;3:1234–1238. doi: 10.1021/bi00897a009. [DOI] [PubMed] [Google Scholar]
  27. Sastrasinh M., Knauss T. C., Weinberg J. M., Humes H. D. Identification of the aminoglycoside binding site in rat renal brush border membranes. J Pharmacol Exp Ther. 1982 Aug;222(2):350–358. [PubMed] [Google Scholar]
  28. Schraufstätter I. U., Browne K., Harris A., Hyslop P. A., Jackson J. H., Quehenberger O., Cochrane C. G. Mechanisms of hypochlorite injury of target cells. J Clin Invest. 1990 Feb;85(2):554–562. doi: 10.1172/JCI114472. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Stead R. J., Hodson M. E., Batten J. C. Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. Br J Dis Chest. 1987 Jul;81(3):272–279. doi: 10.1016/0007-0971(87)90161-6. [DOI] [PubMed] [Google Scholar]
  30. Steinkamp G., Tümmler B., Gappa M., Albus A., Potel J., Döring G., von der Hardt H. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol. 1989;6(2):91–98. doi: 10.1002/ppul.1950060207. [DOI] [PubMed] [Google Scholar]
  31. Suter S., Schaad U. B., Roux L., Nydegger U. E., Waldvogel F. A. Granulocyte neutral proteases and Pseudomonas elastase as possible causes of airway damage in patients with cystic fibrosis. J Infect Dis. 1984 Apr;149(4):523–531. doi: 10.1093/infdis/149.4.523. [DOI] [PubMed] [Google Scholar]
  32. Test S. T., Weiss S. J. Quantitative and temporal characterization of the extracellular H2O2 pool generated by human neutrophils. J Biol Chem. 1984 Jan 10;259(1):399–405. [PubMed] [Google Scholar]
  33. Thomas E. L., Grisham M. B., Jefferson M. M. Preparation and characterization of chloramines. Methods Enzymol. 1986;132:569–585. doi: 10.1016/s0076-6879(86)32042-1. [DOI] [PubMed] [Google Scholar]
  34. Thomas E. L., Jefferson M. M., Grisham M. B. Myeloperoxidase-catalyzed incorporation of amines into proteins: role of hypochlorous acid and dichloramines. Biochemistry. 1982 Nov 23;21(24):6299–6308. doi: 10.1021/bi00267a040. [DOI] [PubMed] [Google Scholar]
  35. Thomas E. L. Lactoperoxidase-catalyzed oxidation of thiocyanate: equilibria between oxidized forms of thiocyanate. Biochemistry. 1981 May 26;20(11):3273–3280. doi: 10.1021/bi00514a045. [DOI] [PubMed] [Google Scholar]
  36. Thompson R. L. The cephalosporins. Mayo Clin Proc. 1977 Oct;52(10):625–630. [PubMed] [Google Scholar]
  37. Turnell D. C., Cooper J. D. Rapid assay for amino acids in serum or urine by pre-column derivatization and reversed-phase liquid chromatography. Clin Chem. 1982 Mar;28(3):527–531. [PubMed] [Google Scholar]
  38. Wall M. A., Terry A. B., Eisenberg J., McNamara M., Cohen R. Inhaled antibiotics in cystic fibrosis. Lancet. 1983 Jun 11;1(8337):1325–1325. doi: 10.1016/s0140-6736(83)92428-5. [DOI] [PubMed] [Google Scholar]
  39. Wasil M., Halliwell B., Moorhouse C. P., Hutchison D. C., Baum H. Biologically-significant scavenging of the myeloperoxidase-derived oxidant hypochlorous acid by some anti-inflammatory drugs. Biochem Pharmacol. 1987 Nov 15;36(22):3847–3850. doi: 10.1016/0006-2952(87)90448-5. [DOI] [PubMed] [Google Scholar]
  40. Weiss S. J. Tissue destruction by neutrophils. N Engl J Med. 1989 Feb 9;320(6):365–376. doi: 10.1056/NEJM198902093200606. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES